Meridian Bioscience (VIVO) Tops Q3 EPS by 7c, Revenues Miss; Offers FY19 EPS Guidance
Tweet Send to a Friend
Meridian Bioscience (NASDAQ: VIVO) reported Q3 EPS of $0.16, $0.07 better than the analyst estimate of $0.09. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
